DR-505 Pan-cancer validation of complementary RNA-seq signatures for HER2 overexpression using Hartwig genomic and transcriptomic data

Patients can benefit from HER2-targeted therapies when their tumors show HER2 activation, but current testing (IHC/FISH) is not always available or consistent across tumor types. We developed two complementary RNA-seq–based signatures: one anchored to HER2 status defined by IHC/FISH in breast and gastric cancer, and one anchored to HER2 protein abundance measured by mass spectrometry in a pan-tumor cohort. Using Hartwig Medical Foundation data (WGS-based copy number and RNA-seq, plus clinical annotations), we will validate how well these signatures identify HER2-driven tumors across cancer types and assess their potential clinical utility.

Kristian Egebjerg, Rigshospitalet, Denmark